ACHIEVEMENT OF SVR12 DESPITE THE PRESENCE OF HCV VARIANTS RESISTANT TO FIRST GENERATION NS5A INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION WITH SOFOSBUVIR

被引：1

作者：

Patel, D. ^{[1
]}

Zhao, Y. ^{[1
]}

Fabrycki, J. ^{[1
]}

Yang, G. ^{[1
]}

Podos, S. ^{[1
]}

Kocinsk, H. ^{[1
]}

Mader, M. ^{[1
]}

Gane, E. ^{[2
]}

Schwabe, C. ^{[3
]}

Apelian, D. ^{[1
]}

Huang, M. ^{[1
]}

Yang, W. ^{[1
]}

机构：

[1] Achill Pharmaceut, New Haven, CT USA

[2] Auckland Hosp, New Zealand Liver Transplant Unit, Auckland, New Zealand

[3] Auckland Clin Studies Ltd, Grafton, New Zealand

来源：

JOURNAL OF HEPATOLOGY | 2015年 / 62卷

关键词：

D O I：

10.1016/S0168-8278(15)31008-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P0805

引用

页码：S636 / S636

页数：1

共 8 条

[1] ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS
Muir, A.
Hill, J.
Lawitz, E.
Marbury, T.
Robarge, L.
Robison, H.
Hui, J.
Huang, M.
Agarwal, A.
Perelson, A.
Deshpande, M.
Kocinsky, H.
JOURNAL OF HEPATOLOGY, 2013, 58 : S360 - S360
[2] PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS
Yang, G.
Wiles, J.
Patel, D.
Zhao, Y.
Fabrycki, J.
Weinheimer, S.
Marlor, C.
Rivera, J.
Wang, Q.
Gadhachanda, V.
Hashimoto, A.
Chen, D.
Pais, G.
Wang, X.
Deshpande, M.
Stauber, K.
Huang, M.
Phadke, A.
JOURNAL OF HEPATOLOGY, 2012, 56 : S330 - S330
[3] Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-naive patients: a Phase 2 "proxy" study
Gane, Edward J.
Kocinsky, Hetal
Schwabe, Christian
Mader, Michael
Suri, Vithika
Donohue, Mary K.
Huang, Mingjun
Hui, James
Yang, Joanna
Apelian, David
HEPATOLOGY, 2014, 60 (06) : 1281A - 1282A
[4] In Vitro Studies Demonstrate a High Probability of Curing Genotype-1 Hepatitis C Patients with Combination of a Novel NS3 Protease Inhibitor ACH-2684 and a Novel NS5A Inhibitor ACH-3102
Zhao, Yongsen
Patel, Dharaben
Fabrycki, Joanne L.
Weinheimer, Samantha
Yang, Guangwei
Yang, Wengang
Deshpande, Milind
Phadke, Avinash
Huang, Mingjun
HEPATOLOGY, 2012, 56 : 1071A - 1072A
[5] Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia
Larousse, Jameleddine Aissa
Trimoulet, Pascale
Pinson, Patricia Recordon
Tauzin, Brigitte
Azzouz, Mohamed Mssadak
Ben Mami, Nabyl
Cheikh, Imed
Triki, Henda
Fleury, Herve
VIROLOGY JOURNAL, 2015, 12
[6] Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia
Jameleddine Aissa Larousse
Pascale Trimoulet
Patricia Recordon Pinson
Brigitte Tauzin
Mohamed Mssadak Azzouz
Nabyl Ben Mami
Imed Cheikh
Henda Triki
Hervé Fleury
Virology Journal, 12
[7] Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: An integrated analysis
McPhee, Fiona
Hernandez, Dennis
Zhou, Nannan
Ueland, Joseph
Vellucci, Vincent
Hartman-Neumann, Sandra
Yang, Xiaoyan
Han, Zhou
Yu, Fei
Yang, Rong
Noviello, Stephanie
HEPATOLOGY, 2015, 62 : 560A - 561A
[8] Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir plus sofosbuvir plus ribavirin
Fedorchenko, Sergii V.
Martynovych, Tatiana
Klimenko, Zhanna
Yanchenko, Vitaliy
Solianyk, Iryna
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (05) : 548 - 551

← 1 →